In 2021, the Medicines and Healthcare Products Regulatory Agency confirmed a possible link between AstraZeneca’s COVID-19 vaccine, known as Vaxzevria, and a rare condition involving blood clots along with abnormally low platelet levels. As a result, patients have launched legal action against AstraZeneca over its COVID-19 vaccine.
Dozens of patients and families are launching legal action against AstraZeneca over a rare side effect of its covid-19 vaccine.
Lawyers have sent the company pre-action protocol letters, the first step in a legal claim on behalf of around 75 claimants. Some have lost relatives and some have survived with catastrophic injuries following blood clots.
Many millions have had the vaccine without suffering complications but in 2021 the Medicines and Healthcare Products Regulatory Agency confirmed a possible link between the vaccine, known as Vaxzevria, and a rare condition involving blood clots along with abnormally low platelet levels. Those taking legal action have been diagnosed with vaccine induced thrombotic thrombocytopenia.
The claimants are pursuing a two pronged strategy: taking legal action under the Consumer Protection Act 1987 as well as claiming payment under the government run Vaccine Damage Payment Scheme. The scheme has paid out in several cases, but is limited to £120 000 per claim and applicants must prove severe disablement.1 Payment under the scheme does not preclude a claim for personal injury through the courts. Those taking action under the Consumer Protection Act must show that the vaccine was not as safe as the public were entitled to expect.
Peter Todd, a consultant solicitor with Scott-Moncrieff & Associates, one of two lawyers handling claims, told The BMJ that the complications included stroke, heart failure, and leg amputations. He said the technology involved in the AstraZeneca vaccine was “risky.”
Join: 👉 https://t.me/acnewspatriots
The opinions expressed by contributors and/or content partners are their own and do not necessarily reflect the views of AC.NEWS
Disclaimer: This article may contain statements that reflect the opinion of the author. The contents of this article are of sole responsibility of the author(s). AC.News will not be responsible for any inaccurate or incorrect statement in this article www.ac.news websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner. Reprinting this article: Non-commercial use OK. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.
Discussion about this post